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Abstract
Background: To evaluate the temporal trends of seroprevalence to pH1N1 among the Guangdong population following
2009 H1N1 pandemic wave, we conducted three cross-sectional serology surveys in 2010.
Methodology/Principal Findings: Three surveys were carried out consecutively in 2010 from January 8 to January 24, from
March 15 to April 10 and from August 23 to September 4. Sample populations comprising of 4725, 4727, and 4721 subjects
respectively were randomly selected for study in these three surveys. The level of antibodies against pH1N1 was evaluated
by hemagglutination inhibition assay. In survey 1, the seroprevalence of pH1N1 among all the subjects is 25.1%, declining to
18.4% in survey 2 and increasing to 21.4% in survey 3. Among vaccinated subjects, the seroprevalence was 49.0%, 53.0%,
and 49.4% in the three consecutive surveys, showing no significant differences. In contrast, among non-vaccinated subjects,
the seroprevalence declined significantly from 22.8% (survey 1) to 14.3% (survey 2) and subsequently increased to 18.1%
(survey 3). The multivariate logistic regression analysis revealed that seroprevalence to pH1N1 in non-vaccinated individuals
correlated with the investigated order of the surveys, age, and region (all P,0.05). However, it was not correlated with
gender (P=0.650), seasonal influenza vaccination history (P=0.402) and symptoms (P=0.074).
Conclusions/Significance: In Guangdong, the seroprevalance to pH1N1 decreased initially and then rebounded modestly
during the first 9 months following the 2009 pandemic wave. Our results suggest that the prevalence of pH1N1 is still
correlated with age and population density during the post-pandemic period. An early end to the free pH1N1 vaccination
program might be another important reason for the slight rebound in seroprevalance. Our study findings can help the
Guangdong authorities to make evidence-based decisions about a long-term vaccination strategy and boost immunity in
specific population groups (such as children and people living in the capital-city) to prevent further transmission in the
future.
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Introduction
In April 2009, a novel influenza virus strain of subtype A
(H1N1) first emerged in the United States [1] and Mexico [2],
later causing a worldwide pandemic. On June 11, 2009, World
Health Organization (WHO) declared a global pandemic for the
first time in the last 41 years [3,4]. In China, the first case of
pandemic H1N1 (pH1N1) was detected on April 30, 2009. In
Guangdong province (a province located in southern China,
a semi-tropical region in Southeast Asian with a population of 100
million), the first case of pH1N1 was reported on May 18, 2009.
From May 1, 2009 to December 31, 2009, a total of 9896
laboratory confirmed cases and 36 pH1N1 deaths were reported
to the Guangdong Notifiable Disease Database. Virological
surveillance documented sustained and widespread community
transmission since early October 2009, followed by a single
epidemic wave which peaked in late November 2009 and subsided
by the end of December 2009 [5].
Despite intensive surveillance for infected cases during the
pandemic [6], it is still very likely that the case reports under-
estimated the true infection rate in the population [7,8] due to the
mis-counting of the asymptomatic and mild cases. Many studies
have been performed to examine the seroprevalence in order to
obtain more accurate evaluations of the true infection rates [9,10],
although few of them were aimed at tracking the temporal trends
of the seroprevalence in the pandemic. As all pandemics in history
are different and the temporal trends in one may not be the case in
other pandemics [11], research on the temporal fluctuations of
pH1N1 is important to give a comprehensive insight into the
transmission feature throughout the duration of the pandemic.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38768The purpose of this study is to understand the impact of the 2009
winter wave of the pH1N1 epidemic and the effect of the free
pH1N1 vaccination program implemented from October 2009 in
Guangdong, to evaluate the risk of recurrence in the 2010 summer
wave, and to explore underlying influencing factors. We con-
ducted three consecutive serological surveys on randomly selected
sample populations from Guangdong in January, March-April and
August-September of 2010 respectively. Combining the findings
from these three surveys will provide valuable information about
the likelihood of potential recurrence and future outbreaks. It will
guide us in formulating vaccination and treatment strategies
during the post-pandemic period. WHO Director-General Dr.
Margaret Chan announced on August 10, 2010 that the global
H1N1 influenza virus had moved into the post-pandemic phase
[12,13].
Methods
Investigation Date
The first survey was conducted from January 11 to January
24, 2010. As the 2009 winter epidemic wave of pH1N1
continued from early October to late December, serology
investigation in January 2010 could help to estimate the extent
of infection during this wave. Considering that the summer
epidemic wave of influenza in Guangdong province usually
happens between March and August [14], the second and third
surveys were performed in March- April (from March 15 to
April 10) and August-September (from August 23 to September
4) 2010 to capture the possible second wave of the pandemic.
(Figure 1) Combining the findings of these three surveys, we
would be able to ascertain a better understanding of the
epidemic characteristics of pH1N1.
Sample Age Groups
The target population fell into five age groups representative of
five categories of people in Guangdong province: toddlers and
preschoolers (0,5 years old), school-age children (6,15 years old),
teens and young adults (16,25 years old), working-age adults
(26,60 years old ) and retired or older adults (60,years old). Each
group has a specific lifestyle and is likely to experience a different
risk of pH1N1 infection.
Sampling Procedures
Based on the residency address, a multi-stage stratified and
cluster random sampling was applied for sample selection in
each survey [15]. Guangdong province, including one capital-
city (Guangzhou city) and twenty middle and small-sized cities
(Figure 2), was divided into three population strata: a) the core
area of the capital city, b) prefectures of other urban areas and
c) prefectures of rural areas. We were instructed to randomly
select at least two districts in each of the three population strata
[16]. By using a random digits table, five urban districts from
the capital-city and twenty districts/counties from twenty middle
Figure 1. Sampling period for three serosurveys shown relative to epidemic curve in Guangdong China. Three surveys were
consecutively carried out in 2010 during 9 months following the 2009 pandemic wave in Guangdong, China. Survey 1 were conducted from January
8 to January 24, survey 2 from March 15 to April 10 and survey 3 from August 23 to September 4.
doi:10.1371/journal.pone.0038768.g001
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sized city) were randomly selected and remained unchanged in
the three surveys. Then at least one street/town in each
district/county and finally at least one community/village in
each street/town were chosen. Once the communities/villages
were selected, the investigating team obtained a name list of all
individuals (including age) residing in the communities/villages
and randomly selected individuals from each sampling age
group. A sample size of 300 from each age group in each
population strata was the target to enroll for each survey. The
selected study subjects were asked by the investigators whether
they would like to participate in the study. If a selected
individual declined to participate, the next individual on the list
was approached and asked to participate. Informed consent had
to be obtained from each study participant before an interview.
Informed consent was provided by adults ($18 years)
themselves. Assent was provided by adolescents (10,17 years),
themselves, and informed consent was given by a parent or
a legal guardian of the adolescent. Informed consent for
children (,10 years) was provided by a parent or a legal
guardian. The survey questionnaire was completed by a trained
interviewer. Blood samples were collected during a face-to-face
interview. The questionnaire included information on the
subject’s age, gender, occupation, vaccination history of seasonal
inuenza (since 2007) and pH1N1, presence/absence of flu-like
illnesses (since May 2009). In total, 4745 study subjects
participated in the first survey, 4773 study subjects participated
in the second survey and 4732 study subjects participated in the
third survey. Excluding the subjects with incomplete question-
naires and invalid blood samples, we finally obtained 4725,
4727 and 4721 valid subjects in the three surveys.
Sample Size
The seroprevalence of pH1N1 was approximately 25% in
China according to sentinel surveillance. With a 95% confidence
interval of +/2 10% (15–35%), we calculated the sample size of
300 from each age group in each of the three strata for an
expected sample size, totaling 4500 subjects for each survey.
Laboratory Methods
Antibodies against the pH1N1 virus were detected by
haemmagglutination inhibition (HI) assay using 0.5% turkey red
Figure 2. Twenty-one cities of Guangdong province were applied by a multi-stage stratified and cluster random sampling for
sample selection in each survey. Guangdong province, including one capital-city (Guangzhou city) and twenty middle and small-sized cities, was
divided into three population strata: a) the core area of the capital city, b) prefectures of other urban areas and c) prefectures of rural areas. At least
two districts in each of the three population strata were randomly selected.
doi:10.1371/journal.pone.0038768.g002
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National Influenza Centres [8,17].The human serum samples
were first treated with receptor-destroying enzyme (RDE) pro-
vided by Chinese National Influenza Center (CNIC) with a ratio
of 4:1 (vol/vol) at 37uC overnight to eliminate nonspecific
inhibitors of hemagglutination. The samples were then incubated
at 56uC for 30 min to inactivate RDE followed by testing for HA-
specific antibodies using the standard hemagglutination inhibition
(HI) assay with A/California/7/2009 employed as antigens. Ten
different dilutions (1:5, 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640,
1:1280, 1:2560) of serum samples were analyzed in virus-specific
assays to evaluate the HA-specific antibody titer. Serum-only
control for each human serum sample without addition of viral
antigen was also assayed in parallel with the virus-specific assays.
Only the virus-specific assays with titer values greater than or
equal to the corresponding serum-only control values were
considered valid. Samples with HI titers $1:40 were considered
as seropositive.
Ethics Statement
This study was approved by the ethics committee of the
Guangdong Center for Disease Control and Prevention and
written informed consent was obtained from the study subjects.
Statistical Analysis
A standard database was created in EPI Data software
(version 3.02). The survey questionnaires were inputted twice
into the database and checked for consistency. Statistical
analyses were performed using SPSS 13.0 software (SPSS Inc.,
Chicago, IL, USA). The seroprevalence was defined as the
percentage of serum titers $40 by HI. Frequencies and
proportions were calculated to describe the demographic
distributions for the three serosurveys. The chi-square test was
used to compare the differences in the seroprevalence among
different groups between each two serosurveys. The significance
level was set as 0.018 to give an overall p-value of 0.05. To
control for possible confounders, multivariable logistic regression
analyses was performed. The dependent variable was the
presence of pH1N1 seropositivity vs. no seropositivity. The
examined independent variables were the investigation order of
the surveys, gender, age, occupation, region (capital city or rural
vs. other urban areas), seasonal influenza vaccination history
and symptoms. The odds ratio (OR) and 95% confidence
interval (95% CI) were calculated for each risk factor.
Significance (P,0.05) was based on Likelihood Ratio test.
The final model examining risk factors for pH1N1 infection
included the investigation order of the surveys, age, and region.
The occupation group was excluded from the model because of
the collinear relationship with age (p,0.001).
Results
Characteristics of Study Subjects
The demographic characteristics of the sampled subjects
changed slightly in the three consecutive surveys, as presented in
Table 1. The median age was 28.3 (range, 1–84) for survey 1, 28.6
(range, 1–86) for survey 2, and 28.2 (range, 1–84) for survey 3.
Male to female ratio was 1:1 in all three surveys. In the three
consecutive surveys respectively, about 8.6% (408/4725), 10.7%
Table 1. Demographic characteristics of the subjects in the
three surveys.
Survey 1 Survey 2 Survey 3
n%n%n%
Age groups (years)
0,5 777 16.4 658 13.9 913 19.3
6,15 1100 23.3 1203 25.4 986 20.9
16,25 991 21.0 972 20.6 963 20.4
26,60 963 20.4 976 20.6 1054 22.3
.60 894 18.9 918 19.4 805 17.1
Gender
Male 2338 49.5 2215 46.9 2318 49.1
Female 2387 50.5 2512 53.1 2403 50.9
Urban/rural
Capital-city 1525 32.3 1527 32.3 1524 32.3
Other urban areas 1679 35.5 1600 33.8 1521 32.2
Rural areas 1521 32.2 1600 33.8 1676 35.5
Occupation
Children scattered 252 5.3 231 4.9 294 6.2
Children in kindergartens 780 16.5 768 16.2 728 15.4
Student 1298 27.5 1264 26.7 1278 27.1
Teacher 161 3.4 174 3.7 96 2.0
Medical personnel 286 6.1 247 5.2 224 4.7
Other 1948 41.2 2043 43.2 2101 44.5
Inoculated with pH1N1 vaccine
Yes 408 8.6 508 10.7 506 10.7
No 4317 91.4 4219 89.3 4215 89.3
Total Number of Cases 4725 100.0 4727 100.0 4721 100.0
doi:10.1371/journal.pone.0038768.t001
Table 2. Pandemic H1N1 seroprevalence in the vaccinated and non-vaccinated people, Guangdong, 2010.
No. Tested (seroprevalence%, 95% CI)
Survey 1 Survey 2 Survey 3
total 4725(25.1, 23.9–26.3) 4727(18.4,17.3–19.5)* 4721(21.4,20.2–22.6)
#*
Vaccinated 408(49.0,44.1–53.9) 508(53.0,48.7–57.3) 506(49.4,45.0–53.8)
Non-vaccinated 4317(22.8,21.5–24.1) 4219(14.3,13.2–15.4)* 4215(18.1,16.9–19.3)
#*
CI:Confidence Interval;
*compared with survey1,P,0.05(by Chi-square);
#compared with survey2, P,0.05(by Chi-square);
doi:10.1371/journal.pone.0038768.t002
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the pH1N1 vaccine since October 2009.
Temporal Trends of the Seroprevalence in Guangdong
Seroprevalence of pH1N1 in Guangdong declined significantly
from 25.1% (95% CI: 23.9–26.3) to 18.4% (95% CI: 17.3–19.5)
between survey 1 and 2, then increased significantly to 21.4%
(95% CI: 20.2–22.6) in survey 3. (Table 2).
Temporal Trends of the Seroprevalence among
Vaccinated Subjects
For subjects who reported receiving the pH1N1 vaccine
(vaccinated subjects), the seroprevalence was 49.0% (95% CI:
44.1–53.9), 53.0% (95% CI: 48.7–57.3), 49.4% (95% CI: 45.0–
53.8) in the three consecutive surveys, respectively. No significant
differences across serosurveys were observed. By comparing the
temporal trends of the seroprevalence with other different positive
titers (HI titer $ 1:20, 1:80, 1:160), we found that the
seroprevalence with titer $ 1:80 and 1:160 dropped noticeable
between survey 2 and 3 (Not shown).
When stratifying by gender, age and region (capital city or rural
vs. other urban areas), the stability of the seroprevalence (HI titer
$ 1:40) across the three surveys persisted, except for two different
strata of region (capital-city and other urban groups). Among the
capital-city group, the seroprevalence increased significantly from
38.6% (95% CI: 35.1–42.1) to 51.1% (95% CI: 48.0–54.2)
between survey 1 and 2, but showed no change between survey 2
and 3. The seroprevalence among the urban group showed no
difference between survey 1 and 2, but declined significantly from
53.0% (95% CI: 48.9–57.1) to 39.1% (95% CI: 35.2–43.0)
between survey 2 and 3 (Table 3). By comparing the temporal
trends of the seroprevalence with other different positive titers (HI
titer $ 1:20, 1:80, 1:160), we found that the seroprevalence with
HI titer $ 1:160 in the capital-city group have been a noticeable
drop between survey 2 and 3 (Not shown).
Temporal Trends of the Seroprevalence among Non-
vaccinated Subjects
For subjects who reported not receiving the pH1N1 vaccine
(non-vaccinated subjects), the seroprevalence declined significantly
from 22.8% (95% CI: 22.2–23.4) to 14.3% (95% CI: 13.8–14.8)
between survey 1 and 2, then increased significantly to 18.1%
(95% CI: 17.5–18.7) in survey 3. Seroprevalence with other
different positive titers (HI titer $ 1:20, 1:80, 1:160) showed
similar temporal trends.
When stratifying by gender, age, occupation, region, seasonal
influenza vaccination history and symptoms, the decline of the
seroprevalence persisted between survey 1 and 2, except for three
different strata of occupation (children scattered, teachers and
medical personnel). No significant differences were observed
among these three strata of occupation (all P.0.018). Between
survey 2 and 3, the increase of the seroprevalence persisted among
different gender groups, three age groups (0,5, 26,60, .60
years), the capital-city group, children in kindergartens, subjects
with other occupations, the seasonal vaccination group and people
without flu-like symptoms (all P,0.018) (Table 4).
The multivariate logistic regression analysis revealed that the
seroprevalence for pH1N1 correlated with the investigated order
of the surveys, age and region (all P,0.05). However, it was not
correlated with gender (P=0.650), seasonal influenza vaccination
history (P=0.402) and symptoms (P=0.074). The occupation
group was excluded from the final regression model because they
had a high correlation with age (P,0.001).
The odds of pH1N1 seropositivity in survey 2 (OR: 0.55, 95%
CI: 0.50–0.62) and survey 3 (OR: 0.75, 95% CI: 0.67–0.83) were
significantly lower than the odds of seropositivity in survey 1. The
odds in survey 3 was significantly higher when compared with that
of survey 2. The odds of pH1N1 seropositivity in the 6,15(OR:
1.20, 95% CI: 1.04–1.37) and 16,25 (OR: 1.17, 95% CI: 1.02–
1.35) age groups were significantly higher when compared with
the odds of seropositivity in the 6,15 age group. However, the
odds of pH1N1 seropositivity in the 26,60 (OR: 1.20, 95% CI:
Table 3. Temporal trends of 2009 H1N1 seroprevalence by demographic characterstics among the vaccinated
subjects,Guangdong, 2010.
No. Tested (seroprevalence%, 95% CI)
Survey 1 Survey 2 Survey 3
Gender
Male 181(51.3, 44.0–58.6) 218(50.9, 44.3–57.5) 245(46.5, 40.3–52.7)
Female 227(47.1, 40.6–53.6) 290(54.4, 48.7–60.1) 261(52.1, 46.0–58.2)
Age group (years)
0,5 25(32.0, 13.7–50.3) 14(42.8, 16.9–68.7) 48(43.7, 29.7–57.7)
6,15 108(52.7, 43.3–62.1) 143(50.3, 42.1–58.5) 167(45.5, 37.9–53.1)
16,25 117(49.5, 40.4–58.6) 149(63.7, 56.0–71.4) 151(57.6, 49.7–65.5)
26,60 136(50.7, 42.3–59.1) 155(49.0, 41.1–56.9) 110(48.1, 38.8–57.4)
.60 22(36.3, 16.2–56.4) 47(42.5, 28.4–56.6) 30(43.3, 25.6–61.0)
Urban/rural
Capital-city 194(38.6, 31.7–45.5) 256(51.1, 45.0–57.2)* 249(53.8, 47.6–60.0) *
Other urban areas 137(59.8, 51.6–68.0) 149(53.0, 45.0–61.0) 156(39.1, 31.4–46.8)
#*
Rural areas 77(55.8, 44.7–66.9) 103(57.2, 47.6–66.8) 101(54.4, 44.7–64.1)
CI:Confidence Interval;
*compared with survey1,P,0.05(by Chi-square);
#compared with survey2, P,0.05(by Chi-square);
doi:10.1371/journal.pone.0038768.t003
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were significantly lower when compared with the odds of
seropositivity in the 6,15 age group. The odds of pH1N1
seropositivity in the urban areas (OR: 0.73, 95% CI: 0.66–0.82)
and the rural areas (OR: 0.79, 95% CI: 0.69–0.90) were
significantly lower when compared with the odds of seropositivity
in the capital city. There was no statistically significant difference
in the odds of seropositivity between urban and rural areas
(Table 5).
Discussion
The 2009 pandemic influenza A (H1N1) virus was a novel
infectious agent to humans [2]. In this study, we conducted three
consecutive serosurveys in 2010 to investigate the temporal trends
of seroprevalence to pH1N1 among vaccinated and non-
vaccinated populations in Guangdong. We aimed to estimate the
effect and implementation of the free pH1N1 vaccination
program, to estimate the recurrence risk of the next pandemic
wave, and explore influencing factors.
Our results demonstrat that seroprevalence to pH1N1 following
the 2009 pandemic among the Guangdong population was 25.1%,
including 49.0% of the vaccinated people and 22.8% of the non-
vaccinated people. The overall seropositive rate declined to 18.4%
in March (survey 2) and rebounded to 21.4% in September (survey
3). Given that seroprevalences among the vaccinated subjects did
not differ significantly across the three surveys, the wave for the
overall seroprevalance may be due to fluctuations in the natural
infection rate with similar activity pattern among non-vaccinated
subjects.
Although no difference in seroprevalance was observed during
the three surveys periods, demographic analysis of the vaccinated
subjects showed that there was a significant growth in seropreva-
lence in the capital-city group from January to March, which was
offset by the reduction in the urban population (people living in
urban areas in middle and small-sized cities) from March to
September. The growth of seroprevalence in the capital-city may
be due to a free pH1N1 vaccination program that had been
implemented since October 2009 in Guangdong. Due to a lack of
detailed data, we are unable to make a definite inference about the
progress of the program in Guangdong. However, it is possible
Table 4. Temporal trends of 2009 H1N1 seroprevalence by inuencing factors among the non-vaccinated subjects, Guangdong,
2010.
No. Tested (seroprevalence%, 95% CI)
Survey 1 Survey 2 Survey 3
Gender
Male 2157(22.1, 20.3–23.9) 1997(15.1, 13.5–16.7)* 2073(18.3, 16.6–20.0)#
Female 2160(23.4, 21.6–25.2) 2222(13.5, 12.1–14.9)* 2142(17.7, 16.1–19.3)#
Age group (years)
0,5 752(28.1, 24.9–31.3) 644(14.4, 11.7–17.1)* 865(19.6, 17.0–22.2)#
6,15 992(28.6, 25.8–31.4) 1060(19.6, 17.2–22.0)* 819(23.5, 20.6–26.4)#
16,25 874(28.6, 25.6–31.6) 823(21.8, 19.0–24.6)* 812(20.9, 18.1–23.7)
26,60 827(15.9, 13.4–18.4) 821(7.7, 5.9–9.5)* 944(14.4, 12.2–16.6)#
.60 872(12.2, 10.0–14.4) 871(6.7, 5.0–8.4* 775(11.8, 9.5–14.1)#
Urban/rural
Capital-city 1331(27.3, 24.9–29.7) 1271(14.1, 12.2–16.0)* 1275(25.4, 23.0–27.8)#
Other urban areas 1542(21.4, 19.4–23.4) 1451(14.9, 13.1–16.7)* 1365(16.7, 14.7–18.7)
Rural areas 1444(20.1, 18.0–22.2) 1497(13.7, 12.0–15.4)* 1575(13.2, 11.5–14.9)
Occupation
Children scattered 245(24.0, 18.7–29.3) 230(15.6, 10.9–20.3) 286(18.8, 14.3–23.3)
Children in kindergartens 757(26.1, 23.0–29.2) 738(13.5, 11.0–16.0)* 686(19.3, 16.3–22.3)#
Student 1169(33.0, 30.3–35.7) 1077(24.5, 21.9–27.1)* 1037(25.3, 22.7–27.9)
Teacher 139(22.3, 15.4–29.2) 140(13.5, 7.8–19.2) 87(20.6, 12.1–29.1)
Medical personnel 105(33.3, 24.3–42.3) 101(22.7, 14.5–30.9) 119(20.1, 12.9–27.3)
Other 1902(14.5, 12.9–16.1) 1933(8.3, 7.1–9.5)* 2000(13.4, 11.9–14.9)#
Vaccination history for seasonal influenza
Yes 461(25.8, 21.8–29.8) 369(14.6, 11.0–18.2)* 309(22.9, 18.2–27.6)#
No 3856(22.4, 21.1–23.7) 3850(14.2, 13.1–15.3)* 3906(17.6, 16.4–18.8)#
With flu-like symptoms
Yes 2491(23.9, 22.2–25.6) 2311(14.4, 13.0–15.8)* 2010(16.9, 15.3–18.5)#
No 1826(21.3, 19.4–23.2) 1908(14.2, 12.6–15.8)* 2205(19.0, 17.4–20.6)#
CI:Confidence Interval;
*compared with survey1,P,0.05(by Chi-square);
#compared with survey2, P,0.05(by Chi-square);
doi:10.1371/journal.pone.0038768.t004
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the middle and small-sized cities ended before February 2010,
whereas the program in the capital-city stopped between March
and September 2010 because seroprevalence with HI titer$ 1:160
decreased significantly during this period. Therefore, the free
vaccination program lasted longer in capital-city areas than in
urban areas. In accordance with this, there was a marked drop
back in seroprevalence in the urban population. It has been
reported in China that the antibody positive rate of pH1N1 in
vaccinated people would reach a maximum (81%) at day 30
(calculated since the first day of vaccination) and then began to
drop[18–20]. It is likely that the decline of the seroprevalence in
urban areas was a result of the quick drop in antibody levels
among the population from this group. However, we cannot
exclude the involvement of other influencing factors in developing
this wave of seroprevalence.
Among non-vaccinated subjects, seroprevalence declined
significantly from 22.8% to 14.3% between January and March.
This is consistent with the data from Guangdong Notifiable
Disease Database, which showed that the number of reported
pH1N1 cases per day decreased gradually between January and
March. A previous study in China also found that antibody
positive rates of pH1N1 in patients would reach a maximum
(100%) at day 30 (calculated since the first day of onset of the
disease) and then begin to drop [18]. So the decline in
seroprevalence from January to March is probably due to the
quick decrease in protective antibodies in old cases and the
reduction of newly reported cases. Such a decline was found
among all evaluated demographic groups except for children
scattered, teachers, and medical personnel. Teachers and medical
personnel are in close contact with high risk population such as
students and patients, which would increase their exposure to the
H1N1 virus [21].
Seroprevalence in non-vaccinated subjects increased significant-
ly by 26.6% from March to September. This is inconsistent with
the report from GD Notifiable Disease Database, in which the
number of reported H1N1 cases fluctuated at a low level between
March and September. However, it is similar to findings from
Outpatient Influenza-like Illness Sentinel Surveillance System
which demonstrated a small peak in ILI% (percentage of visits for
influenza-like illness) in July 2010, with the proportion for
influenza A (H1N1) among ILI positive samples collected from
sentinel hospitals also increasing progressively since late June and
reaching a small peak (approximately 40%) in late July. The
reason for the inconsistency between GD Notifiable Disease
Database and Sentinel Surveillance System is that the Notifiable
Disease Database is based on passive reporting by health care
providers and is less sensitive when compared to active sentinel
and serologic surveillance.
Although 26,60 and .60 years age groups increased their
seroprevalences between March and September, the multivar-
iate analysis found that the school-aged population and young
adults (6,15 and 16,25 years) had a higher risk of infection
by pH1N1 for those whose seroprevalences remained highest in
the three serosurveys. This is consistent with the studies [21,22]
from the 2009 pandemic period that suggests the notion that
school aged children constitute the main conduit for the spread
of influenza due to generally higher levels of contact in school.
The finding that people in the capital city had higher risk of
infection by pH1N1 than other regions also accords with the
studies from the 2009 pandemic period, which is explained by
more frequent social contact and greater population density in
the capital city.
The association between the investigation order of the surveys
and the prevalence of pH1N1 indicates that the temporal trends of
seroprevalence among the non-vaccinated population are related
to other factors as well as age and region. The most probable
influencing factor we speculate is the vaccination strategy which
was the most effective control measure taken in 2009–2010 by
Guangdong authorities because vaccinated people play a barrier
role in sustainable human-to-human transmission among the non-
vaccinated population. As noted earlier, the free pH1N1
vaccination program began in October 2009 and ended before
September 2010 in Guangdong. The free pH1N1 vaccination
program helped restrain the possible summer wave of 2010 in
Guangdong, but abandoning the program too soon resulted in the
slight rebounding of seroprevalence in September 2010.
Several studies reported that previous seasonal influenza
vaccinations were associated with higher HI titers against H1N1
[23–25]. In our study, seroprevalence in the two groups (with or
without seasonal influenza vaccination) were similar. We found
a greater decrease in the seropositive rate in the seasonal influenza
vaccination group between January and March. Further studies
are needed to focus on the relationship between seasonal influenza
vaccination history and the seropositive rate to pH1N1.
According to the three surveys, approximately 39.5% (389/
985), 44.9% (271/603) and 55.2% (420/731) of the seropositive
individuals (non-pH1N1-vaccinated) did not have flu-like symp-
toms (one or more symptoms) since May 2009. The multivariate
analysis did not find a correlation between flu-like symptoms and
seroprevalence to pH1N1. Nevertheless, the role of asymptomatic
Table 5. Logistic regression analysis of factors associated
with 2009 H1N1 seroprevalence among the non-vaccinated
subjects, Guangdong, 2010.
B OR(95%CI) P
Investigation order of the surveys
Survey 1 1
Survey 2 20.59 0.55(0.50–0.62) ,0.001
Survey 3 20.29 0.75(0.67–0.83) ,0.001
Gender
Male 20.02 0.98(0.89–1.07) 0.650
Female 1
Age group (years)
0,51
6,15 0.18 1.20(1.04–1.37) 0.010
16,25 0.16 1.17(1.02–1.35) 0.027
26,60 20.61 0.54(0.46–0.64) ,0.001
.60 20.88 0.41(0.35–0.49) ,0.001
Region
Capital-city 1
Other urban areas 0.31 0.73(0.66–0.82) ,0.001
Rural areas 0.46 0.63(0.56–0.71) ,0.001
Vaccination history for seasonal influenza
Yes 20.07 0.93(0.80–1.10) 0.402
No 1
With flu-like symptoms
Yes 20.08 0.92(0.84–1.01) 0.074
No 1
doi:10.1371/journal.pone.0038768.t005
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because it has important implications in formulating public health
policy that are instituted at ports of entry and at educational
institutions during the first pandemic wave and it underscores the
need for vigilance at both the community and individual levels to
control the spread of disease.
Limitations
It is important to note several limitations of this study. Firstly,
there was no pre-pandemic or early pandemic collection as
a baseline which would have been useful to estimate the attack rate
or seroprevalence of pH1N1 infection after the 2009 wave of
pH1N1 infection. as the seropositivity would decline after 30 days
post-infection, the surveys collected in January and September
2010 may have already been too late to capture the pandemic
peak. Secondly, the lack of data on indicators of influenza-like
illness (such as hospital admission rates), vaccination rates and the
period during which vaccinations took place in the region resulted
inability to link results to these factors more directly. Finally,
though we recorded a high percentage of the seropositive
individuals who did not report flu-like symptoms, this may be
partly due to potential recall bias.
Conclusion
In Guangdong, seroprevalance to pH1N1 decreased firstly and
then rebounded modestly during the first 9 months following the
2009 pandemic wave of the disease. The free pH1N1 vaccination
program carried out smoothly since October 2009 maintained
stability with the seroprevalances of the three surveys among the
vaccinated population and helped restrain a possible summer wave
in 2010 among the non-vaccinated population. Our results suggest
that the prevalence of pH1N1 among the non-vaccinated
population still correlated with age and population density during
the post-pandemic period. An early end of the free pH1N1
vaccination program might be another important reason for the
slight rebound in seroprevalance to pH1N1 in 2010. Our study
findings can help Guangdong authorities make evidence-based
decisions about a long-term vaccination strategy and boost
immunity in specific population groups (such as children, capital
city residents) to prevent further transmission in the future.
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